

Clinical and Applied Thrombosis/Hemostasis

<http://cat.sagepub.com>

Erratum

Clin Appl Thromb Hemost 2002; 8; 212

DOI: 10.1177/107602960200800302

The online version of this article can be found at:

<http://cat.sagepub.com>

Published by:



<http://www.sagepublications.com>

Additional services and information for *Clinical and Applied Thrombosis/Hemostasis* can be found at:

Email Alerts: <http://cat.sagepub.com/cgi/alerts>

Subscriptions: <http://cat.sagepub.com/subscriptions>

Reprints: <http://www.sagepub.com/journalsReprints.nav>

Permissions: <http://www.sagepub.com/journalsPermissions.nav>

125. Rice L, Nichol JL, McMillan R, Roskos LK, Bacile M. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. *Am J Hematol* 2001;68:210.
126. Haznedaroglu IC, Savas CM, Benkli M, Gullu IH, Dunder SV. The significance of megakaryocytopoietic cytokines and thrombopoietin in immune thrombocytopenic purpura: a hypothesis. *NZ Med J* 1996;109:389.
127. Bassler RL, Rasko JE, Clarke K, Cebon J, Green MD, Hussein S, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. *Lancet* 1996;348:1279.
128. Bassler RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. *Blood* 1997;89:3118.
129. Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. *N Engl J Med* 1997;336:404.
130. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelka AP, Freedman RS, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. *Ann Intern Med* 2000;132:364.
131. Abraham R, Bassler RL. Megakaryocyte growth and development factor: A review of early clinical studies. *Oncologist* 1997;2:311.
132. Miyazaki H, Kato T. Thrombopoietin: Biology and clinical potentials. *Int J Hematol* 1999;70:216.
133. Dan K, Nomura S, Hotta T, et al. Biological effect of pegylated recombinant megakaryocyte growth and development factor (PEG-MGDF) in patients with idiopathic thrombocytopenic purpura. *Blood*. 2001;98:299a.
134. Harker LA, Marzec UM, Novembre F, Sundell IB, Waller EK, Karpatkin S, et al. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor. *Blood* 1998;91:4427.
135. Nakamura M, Toombs CF, Duarte IG, Ronson RS, Schmarkey LS, Katzmark SL, et al. Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia. *Ann Thorac Surg* 1998;66:1216.
136. Kuter DJ. Future directions with platelet growth factors. *Semin Hematol* 2000;37:41.
137. Case BC, Hauck ML, Yeager RL, Simkins AH, de Serres M, Schmith VD, et al. The pharmacokinetics and pharmacodynamics of GW395058, a peptide agonist of the thrombopoietin receptor, in the dog, a large-animal model of chemotherapy-induced thrombocytopenia. *Stem Cells* 2000;18:360.
138. Farese AM, Casey DB, Smith WG, Vigneulle RM, McKearn JP, MacVittie TJ. Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: Effect of schedule, dose, and route of administration. *Stem Cells* 2001;19:522.
139. Bassler RL, Begley CG. Failing to live up to the fanfare? A personal perspective on obstacles to the clinical development of thrombopoietic agents. *Int J Hematol* 2001;74:390.

ERRATUM

In the January 2002 issue of *Clinical and Applied Thrombosis/Hemostasis*, "Effects of Extracorporeal Circulation on Thrombin-Antithrombin III and Prothrombin Fragment 1+2 Levels" (Yilmaz M, Haznedaroglu IC, Kirazli S, and Pasaoglu I. *Clin Appl Thrombosis/Hemostasis* 2002;8:61-63).

On p. 62 under the "Materials and Methods" section, in the first line of the first sentence, the word "sixteen" should be "twenty." The authors regret the error.